Tvardi Therapeutics (NASDAQ:TVRD) Research Coverage Started at Chardan Capital

Chardan Capital started coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a research note released on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating on the stock.

Other equities analysts also recently issued research reports about the company. Piper Sandler upgraded Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research note on Wednesday, July 8th. BTIG Research decreased their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research note on Wednesday, July 8th. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research report on Wednesday, July 8th. Finally, Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $9.40.

Tvardi Therapeutics Stock Performance

TVRD opened at $0.97 on Tuesday. The firm has a 50-day moving average of $1.50 and a 200 day moving average of $2.42. Tvardi Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $5.69.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, equities analysts forecast that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. GSA Capital Partners LLP bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth approximately $34,000. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at $63,000. Finally, BlackRock Inc. purchased a new position in Tvardi Therapeutics in the 2nd quarter worth $181,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.